Therapeutics
Search By Attributes
Search Results
| Name | Synonyms | FDA Status | Company | Target Type | Therapy Type | Approved For |
|---|---|---|---|---|---|---|
| ABBV-916 | N3pG-Abeta mAb | Alzheimer's Disease (Phase 2) | Amyloid-Related | Immunotherapy (passive) | ||
| AL101 | GSK-4527226 | Alzheimer's Disease (Phase 2) | Alector, GlaxoSmithKline (GSK) | Other | Immunotherapy (passive) | |
| Bepranemab | UCB0107, UCB 0107, Antibody D |
Progressive Supranuclear Palsy (Phase 1), Alzheimer's Disease (Phase 2) | Hoffmann-La Roche, UCB S.A. | Tau | Immunotherapy (passive) | |
| BMS-986446 | PRX005 | Alzheimer's Disease (Phase 2) | Bristol-Myers Squibb, Prothena | Tau | Immunotherapy (passive) | |
| Etanercept | Enbrel™ | Alzheimer's Disease (Phase 2) | Amgen, Inc., Pfizer | Inflammation | Immunotherapy (passive) | Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondilysis |
| Foralumab | TZLS-401, NI-0401, 28F11-AE |
Alzheimer's Disease (Phase 2) | Tiziana Life Sciences | Inflammation | Immunotherapy (passive) | |
| SHR-1707 | Alzheimer's Disease (Phase 2) | Amyloid-Related | Immunotherapy (passive) |